文献速递胸部肿瘤骨软组织肉瘤与黑色素瘤

89Zr-帕博利珠单抗成像作为无创评估癌症PD-1阻断临床反应的方法

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
PubMed 文献 · Ann Oncol · 2021-11-01

该研究在晚期或转移性黑色素瘤及非小细胞肺癌患者中,于PD-1抗体治疗前进行89Zr-帕博利珠单抗PET成像。18例患者中,肿瘤SUVmax与治疗反应、无进展生存和总生存相关。最佳剂量为5 mg帕博利珠单抗,最佳扫描时间为第7天。

要点

  • 89Zr-帕博利珠单抗肿瘤摄取与治疗反应(P趋势=0.014)、无进展生存(P=0.0025)和总生存(P=0.026)相关。
  • 最佳剂量为5 mg帕博利珠单抗,最佳PET扫描时间点为第7天。
  • 黑色素瘤与非小细胞肺癌的肿瘤SUVmax无显著差异(4.9 vs 6.5,P=0.49)。

核心结论

  • 肿瘤病灶的89Zr-帕博利珠单抗摄取与治疗反应和患者生存相关。
  • 89Zr-帕博利珠单抗在淋巴组织和炎症部位也有摄取。

研究设计与样本

  • 研究为在PD-1抗体治疗前进行的89Zr-帕博利珠单抗PET成像研究。
  • 纳入18例晚期或转移性黑色素瘤(11例)或非小细胞肺癌(7例)患者。
  • 患者接受37 MBq(1 mCi)89Zr-帕博利珠单抗(约2.5 mg抗体)静脉注射,外加2.5或7.5 mg未标记帕博利珠单抗。
  • 随后在第2、4和7天进行最多三次PET扫描,之后开始PD-1抗体治疗。

主要发现

  • 肿瘤89Zr-帕博利珠单抗摄取与肿瘤反应相关(P趋势=0.014)。
  • 肿瘤89Zr-帕博利珠单抗摄取与无进展生存相关(P=0.0025)。
  • 肿瘤89Zr-帕博利珠单抗摄取与总生存相关(P=0.026)。
  • 肿瘤SUVmax在黑色素瘤和非小细胞肺癌之间无显著差异(4.9 vs 6.5,P=0.49)。
  • 5 mg剂量下89Zr-帕博利珠单抗摄取在脾脏最高,平均SUVmean为5.8(标准差±1.8)。

关键数值与推荐

  • 肿瘤89Zr-帕博利珠单抗摄取以最大标准化摄取值(SUVmax)计算,并以几何均值表示。
  • 正常器官摄取以平均标准化摄取值(SUVmean)计算,并以均值表示。
  • 肿瘤反应根据(i)RECIST v1.1评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed cell death protein 1 (PD-1) antibody treatment is standard of care for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which patients will benefit is currently not possible. Tumor uptake and biodistribution of the PD-1 antibody might play a role. Therefore, we carried out a positron emission tomography (PET) imaging study with zirconium-89 (89Zr)-labeled pembrolizumab before PD-1 antibody treatment. PATIENTS AND METHODS: Patients with advanced or metastatic melanoma or NSCLC received 37 MBq (1 mCi) 89Zr-pembrolizumab (∼2.5 mg antibody) intravenously plus 2.5 or 7.5 mg unlabeled pembrolizumab. After that, up to three PET scans were carried out on days 2, 4, and 7. Next, PD-1 antibody treatment was initiated. 89Zr-pembrolizumab tumor uptake was calculated as maximum standardized uptake value (SUVmax) and expressed as geometric mean. Normal organ uptake was calculated as SUVmean and expressed as a mean. Tumor response was assessed according to (i)RECIST v1.1. RESULTS: Eighteen patients, 11 with melanoma and 7 with NSCLC, were included. The optimal dose was 5 mg pembrolizumab, and the optimal time point for PET scanning was day 7. The tumor SUVmax did not differ between melanoma and NSCLC (4.9 and 6.5, P = 0.49). Tumor 89Zr-pembrolizumab uptake correlated with tumor response (P trend = 0.014) and progression-free (P = 0.0025) and overall survival (P = 0.026). 89Zr-pembrolizumab uptake at 5 mg was highest in the spleen with a mean SUVmean of 5.8 (standard deviation ±1.8). There was also 89Zr-pembrolizumab uptake in Waldeyer's ring, in normal lymph nodes, and at sites of inflammation. CONCLUSION: 89Zr-pembrolizumab uptake in tumor lesions correlated with treatment response and patient survival. 89Zr-pembrolizumab also showed uptake in lymphoid tissues and at sites of inflammation.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kok IC, Hooiveld JS, van de Donk PP, et al. 89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann Oncol. 2021. PMID: 34736925. doi:10.1016/j.annonc.2021.10.213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。